Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Transcutaneous Spinal Cord Stimulation for Motor Recovery After Spinal Cord Injury

13. November 2026 aktualisiert von: Dr. Gabriel Zeilig

Restoring Upper and Lower Extremity Functions in Persons With Spinal Cord Injury by Transcutaneous Spinal Cord Stimulation

This study will examine the safety, feasibility, and potential benefits of transcutaneous spinal cord stimulation (scTS) combined with activity-based training in people with spinal cord injury.

The study will include 10 adults with chronic, incomplete spinal cord injury. Electrical stimulation will be delivered through electrodes placed on the skin over different regions of the spinal cord, while participants perform exercises involving the arms, hands, trunk, and legs.

Participants will undergo initial assessments, individualized stimulation mapping, and 80 training sessions, followed by final assessments. Researchers will evaluate changes in motor function, muscle activity, psychological well-being, autonomic function, and quality of life. Safety and tolerability will also be monitored throughout the study.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This prospective, single-arm, within-subject exploratory study will enroll 10 adults aged 18-65 years with chronic incomplete cervical or thoracic spinal cord injury.

The study includes four phases: (1) baseline assessments over approximately two months; (2) stimulation mapping and optimization over approximately 0.5-1 month to identify individualized stimulation parameters; (3) 80 sessions of multisegment transcutaneous spinal cord stimulation combined with activity-based training, delivered 3-5 days per week over approximately 4-7 months; and (4) follow-up assessments.

The intervention targets upper and lower extremity function, trunk control, standing, and stepping. Motor performance will be assessed primarily using the Neuromuscular Recovery Scale (NRS). Additional assessments will examine muscle activation using electromyography (EMG), psychological symptoms, autonomic function, neurological status, spasticity, functional independence, and quality of life.

Intermediate assessments will be conducted during the intervention, including after 40 training sessions. Safety, adverse events, and feasibility will be evaluated throughout the study.

Studientyp

Interventionell

Einschreibung (Geschätzt)

10

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Ramat Gan, Israel
        • Sheba Medical Center
        • Kontakt:
        • Unterermittler:
          • Einat Haber, M.D.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. At least 18 years of age.
  2. Non-progressive cervical or thoracic (>T10) spinal cord injury (SCI), with the ability to voluntarily move at least three joints below the injury level.
  3. At least 6 months post spinal cord injury.
  4. Stable medical condition.
  5. Neuromuscular Recovery Scale (NRS) score <4C on any upper extremity, trunk, or standing/stepping item.

Exclusion Criteria:

  1. Ventilator dependence.
  2. Untreated or unstable fracture or pressure ulcer.
  3. Untreated psychiatric disorder or ongoing drug abuse.
  4. Cardiac, respiratory, bladder, renal, or other medical disorder that may interfere with the study.
  5. Skeletal muscle Botox injections within the previous 6 months.
  6. Previous nerve or tendon transfer of the arms or legs.
  7. Any implanted pump (e.g., baclofen pump or pain pump).
  8. Unable or unwilling to discontinue anti-spasticity medications.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Multisegment scTS + Activity-Based Training

Participants will receive individualized multisegment transcutaneous spinal cord stimulation (scTS) combined with activity-based training targeting upper and lower extremity function, trunk control, standing, and stepping. The intervention will consist of 80 training sessions, delivered 3-5 days per week over approximately 4-7 months, with sessions lasting up to 2 hours.

Non-invasive electrical stimulation delivered through surface electrodes placed over multiple spinal levels using the NeoStim-5 system. Stimulation sites and parameters will be individually optimized to facilitate motor activation of the upper extremities, trunk, and lower extremities during activity-based training.

Individualized, task-specific rehabilitation training targeting voluntary control of the hands, arms, trunk, and legs, including seated activities, standing, and stepping. Training will be provided by rehabilitation staff and combined with transcutaneous spinal cord stimulation.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Motor Function (NRS)
Zeitfenster: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in motor performance assessed using the Neuromuscular Recovery Scale (NRS), which evaluates movement quality and the level of assistance required during upper extremity, trunk, standing, and stepping tasks. Changes in individual task ratings will be assessed across study time points.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Safety
Zeitfenster: From enrollment through the final study assessment (approximately 7-10 months per participant).

Incidence of adverse events and equipment-related complications during the study. Adverse events will be categorized by severity, relatedness to study procedures, and expectedness.

From enrollment through the final study assessment (approximately 7-10 months per participant).

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Surface EMG Amplitude During Functional Motor Tasks
Zeitfenster: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in surface electromyography (EMG) signal amplitude during functional motor tasks involving upper extremity, trunk, and lower extremity muscles.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Depression (PHQ-9)
Zeitfenster: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in depressive symptoms measured using the 9-item Patient Health Questionnaire (PHQ-9). Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Anxiety (GAD-7)
Zeitfenster: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in anxiety symptoms measured using the 7-item Generalized Anxiety Disorder scale (GAD-7). Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
PTSD (PCL-5)
Zeitfenster: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training)

Changes in self-reported post-traumatic stress symptoms measured using the PTSD Checklist for DSM-5 (PCL-5). Total scores range from 0 to 80, with higher scores indicating greater symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training)
PTSD (CAPS-5)
Zeitfenster: Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).

Changes in clinician-rated post-traumatic stress symptom severity measured using the CAPS-5. The total severity score ranges from 0 to 80, with higher scores indicating greater symptom severity.

Baseline, after 40 training sessions, and after 80 training sessions (approximately 4-7 months of training).
Change in ISNCSCI Total Motor Score
Zeitfenster: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in motor function assessed using the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). The total motor score ranges from 0 to 100, with higher scores indicating better motor function.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Modified Ashworth Scale (MAS) Score
Zeitfenster: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in muscle spasticity assessed by a clinician using the Modified Ashworth Scale, which grades resistance to passive movement.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Spinal Cord Injury Spasticity Evaluation Tool (SCI-SET) Score
Zeitfenster: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in the self-reported impact of spasticity on daily activities, assessed using the SCI-SET questionnaire covering the preceding seven days.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Autonomic Dysfunction Following Spinal Cord Injury (ADFSCI) Questionnaire Score
Zeitfenster: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in frequency and severity of symptoms associated with blood pressure instability, assessed using the 24-item ADFSCI questionnaire.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Modified Functional Reach Test Distance
Zeitfenster: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in maximum forward reaching distance while seated, measured using the Modified Functional Reach Test

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)
Change in Activity-Based Balance Level (ABLE) Sitting Subscale Score
Zeitfenster: Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Change in sitting balance assessed using the seven items of the ABLE sitting subscale, with a maximum score of 32.

Baseline and post-training assessment (after 80 training sessions; approximately 4-7 months of training)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

1. Januar 2029

Studienabschluss (Geschätzt)

1. Januar 2030

Studienanmeldedaten

Zuerst eingereicht

8. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • SHEBA-26-3283-GZ-CTIL

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .